<DOC>
	<DOCNO>NCT00378768</DOCNO>
	<brief_summary>RATIONALE : Biological therapy , antithymocyte globulin , may stimulate immune system different way stop cancer cell grow . PURPOSE : This phase II trial study well antithymocyte globulin work treat patient undergoing stem cell transplant multiple myeloma .</brief_summary>
	<brief_title>Antithymocyte Globulin Treating Patients Undergoing Stem Cell Transplant Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate 4 week patient multiple myeloma treat anti-thymocyte globulin least 4 6 week prior undergo condition therapy allogeneic autologous stem cell transplantation . Secondary - Determine toxicity drug , term formation antirabbit antibody , patient . OUTLINE : This open-label , multicenter study . Patients receive anti-thymocyte globulin IV 6 hour day 1 4 hour day 3 5 . Treatment begin 4 6 week prior undergo condition therapy autologous allogeneic stem cell transplantation . After completion study treatment , patient follow 28 day . PROJECTED ACCRUAL : A total 12 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm multiple myeloma Candidate autologous allogeneic stem cell transplantation within 1 3 month study treatment Measurable disease , define serum monoclonal protein ≥ 1 g/dL OR urinary light chain excretion = 500 mg/24 hour No malignant CNS disease PATIENT CHARACTERISTICS : Life expectancy ≥ 6 month Absolute neutrophil count ≥ 1,000/mm³ Platelet count &gt; 50,000/mm³ Creatinine ≤ 2 mg/dL Hepatic function ≤ 2 time upper limit normal DLCO ≥ 50 % No active infection No hypersensitivity rabbit proteins No symptomatic hyperviscosity syndrome Negative pregnancy test PRIOR CONCURRENT THERAPY : More 28 day since prior chemotherapy , include prednisone ( 20 mg equivalent/day ) No prior antithymocyte globulin No concurrent radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
</DOC>